ArticleBMC gastroenterology2025
A chitinase-3-like protein-1-based nomogram for identification of significant liver fibrosis in the general population.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Serum Chitinase-3-Like Protein 1 with Liver Fibrosis Severity in Autoimmune Liver Diseases.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum chitinase-3-like protein-1 (CHI3L1) level is significantly correlated with fibrosis in chronic liver diseases. Therefore, we aimed to develop a CHI3L1-based model to predict significant liver fibrosis in the general population.
methodsThis retrospective cross-sectional study enrolled 6361 participants (4452 training and 1909 validation). Least absolute shrinkage and selection operator (LASSO) with variance inflation factor (VIF) analysis was employed for variable selection. Multivariable logistic regression analyses were used to construct a nomogram model. The clinical utility of the nomogram model was compared with that of the fibrosis-4 index (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS) using receiver operating characteristic curves with comparisons of areas under the curve (AUCs), decision curve analysis (DCA), clinical impact curves (CIC), and stratified subgroup analysis.
resultsThe nomogram model was composed of five variables: waist circumference, body mass index, aspartate aminotransferase, homeostatic model assessment of insulin resistance, and CHI3L1. The model obtained AUCs of 0.795 and 0.802 in the training and validation cohorts, respectively, which were significantly greater than those of FIB-4, NFS, and CHI3L1 alone, ranging from 0.573 to 0.612. Furthermore, DCA demonstrated greater net benefit across clinically relevant threshold, while CIC confirmed robust risk stratification. Consistent performance was observed in the metabolic dysfunction-associated steatotic liver disease (MASLD) population.
conclusionsThis novel nomogram showed good performance and clinical utility in predicting significant liver fibrosis and could be used as an ideal screening tool for the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.